読み込み中
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
前日終値
$99.60
+$1.11 · +1.13%
日中の時刻はETです。市場データは遅延する場合があります。
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
日中レンジ
現在 $99.60
52週レンジ
現在 $99.60
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
83
大幅な割安
センチメント
72
強気
リスク
31
中程度のリスク
モメンタム
38
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
日中レンジ
現在 $99.60
52週レンジ
現在 $99.60
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$119.91
上昇余地（20.39%）分割調整後の1株当たりの年間現金分配金。
$2.36
2025年（通年）+31.1% 以来 2021
2026年（一部）：$1.89
$1.80
2,021
$1.88
2,022
$2.04
2,023
$2.20
2,024
$2.36
2,025
$1.89
2,026*
* 利用可能な配当履歴のうち、暦年の一部のみを含みます。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当予定 | 2026年10月15日 | $0.63Quarterly | 2026年10月15日 | 2026年11月16日 |
配当 | 2026年7月15日 | $0.63Quarterly | 2026年7月15日 | 2026年8月17日 |
配当 | 2026年4月15日 | $0.63Quarterly | 2026年4月15日 | 2026年5月15日 |
配当 | 2026年1月15日 | $0.63Quarterly | 2026年1月15日 | 2026年2月13日 |
配当 | 2025年10月15日 | $0.59Quarterly | 2025年10月15日 | 2025年11月17日 |
配当 | 2025年7月15日 | $0.59Quarterly | 2025年7月15日 | 2025年8月15日 |
配当落ち 2026年10月15日
$0.63
Quarterly
2026年10月15日基準 · 支払日 2026年11月16日
配当落ち 2026年7月15日
$0.63
Quarterly
2026年7月15日基準 · 支払日 2026年8月17日
配当落ち 2026年4月15日
$0.63
Quarterly
2026年4月15日基準 · 支払日 2026年5月15日
配当落ち 2026年1月15日
$0.63
Quarterly
2026年1月15日基準 · 支払日 2026年2月13日
配当落ち 2025年10月15日
$0.59
Quarterly
2025年10月15日基準 · 支払日 2025年11月17日
配当落ち 2025年7月15日
$0.59
Quarterly
2025年7月15日基準 · 支払日 2025年8月15日
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P 500 ETF1557.T3293.07億0.25%129.34兆 JPY0.09%￥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI61.09億0.26%2.3兆 USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO51.07億0.29%1.8兆 USD0.03%$715.59+0.61%
Schwab U.S. Dividend Equity ETFSCHD41.21億3.74%1103.15億 USD0.06%$33.04-0.32%
iShares Core S&P 500 ETFIVV22.66億0.25%8964.4億 USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY20.8億0.25%8172億 USD0.09%$778.57+0.60%
Vanguard Morningstar Value ETFVTV18.37億0.70%2624億 USD0.03%$220.59+0.44%
State Street Health Care Select Sector SPDR ETFXLV12.14億2.79%435.37億 USD0.08%$170.81+1.58%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOSchwab U.S. Dividend Equity ETFSCHDiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVState Street Health Care Select Sector SPDR ETFXLVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
